Olmsted syndrome
Olmsted's syndrome; mutilating palmoplantar keratoderma with periorificial keratotic plaques (one of the rare mutilating PPK syndromes alongside Vohwinkel)
Olmsted syndrome is a rare autosomal dominant (occasionally recessive) mutilating palmoplantar keratoderma syndrome caused by germline gain-of-function mutations of TRPV3 on chromosome 17p13.2 — a thermosensitive cation channel of the transient receptor potential family expressed in keratinocytes. The cardinal phenotype is a severe mutilating diffuse palmoplantar keratoderma developing in infancy, accompanied by characteristic periorificial keratotic plaques (perioral, perinasal, periocular, perigenital, perianal), alopecia, nail dystrophy, intractable pruritus and (in some patients) deafness, corneal lesions, joint contractures and skeletal anomalies. The skin-oncology importance is the elevated lifetime risk of squamous cell carcinoma arising in long-standing palmoplantar keratotic plaques (~5–10%) — Marjolin-spectrum behaviour with substantial metastatic risk in the rare patient who survives to adulthood with chronic, non-healing keratotic plaques. Recognition by the dermatologist or paediatric dermatologist is critical; emerging targeted therapy with TRPV3 antagonists offers hope.
Genetics
- Germline gain-of-function mutations of TRPV3 on chromosome 17p13.2 — encodes a thermosensitive cation channel expressed in keratinocytes that regulates skin barrier formation, hair growth and itch.
- Most cases sporadic / autosomal dominant; rare autosomal recessive variants described.
- Confirm by germline TRPV3 sequencing.
Cardinal clinical features
- Mutilating diffuse palmoplantar keratoderma:
- Onset in infancy.
- Severe diffuse hyperkeratosis of the palms and soles, often with a sharply demarcated erythematous border.
- Progressive contractures, autoamputation and pseudoainhum (constricting fibrous bands at the digits) in long-standing disease.
- Functionally disabling.
- Periorificial keratotic plaques:
- Symmetric hyperkeratotic plaques around the mouth, nose, eyes, anus, vulva / scrotum.
- Develop in infancy / early childhood.
- Pathognomonic when combined with palmoplantar keratoderma.
- Alopecia — universal alopecia (scalp, eyebrows, eyelashes, body hair).
- Nail dystrophy — onycholysis, onychogryphosis, leuconychia.
- Intractable pruritus — TRPV3-mediated; difficult to control.
- Other — deafness, corneal opacity, joint contractures, dental anomalies, recurrent infections.
Cancer risk — Marjolin-spectrum SCC
- Lifetime risk of squamous cell carcinoma arising in long-standing palmoplantar keratotic plaques ~5–10%.
- Behaves as a Marjolin-spectrum SCC (see monograph) with chronic inflammation as the substrate; substantial metastatic risk.
- Latency typically decades from onset of keratoderma.
- Warning signs:
- New non-healing ulcer or exophytic mass within an established keratotic plaque.
- Pain disproportionate to the patient's chronic baseline.
- Bleeding.
- Rapid growth or change in surface character.
- Multiple deep biopsies of any change; manage as Marjolin SCC.
Management
- Multidisciplinary care — dermatology, plastic surgery, ophthalmology, audiology, paediatric / general genetics, podiatry; lifelong.
- Skin care:
- Daily emollients and keratolytics (urea 10–40%, salicylic acid 5–10%, topical retinoids).
- Oral retinoids (acitretin) — the most effective standard therapy; lifelong.
- Topical / oral antibiotics / antifungals for secondary infection.
- Topical mTOR inhibitors (sirolimus) — case reports of efficacy.
- Pressure-relieving footwear; podiatry; physiotherapy for contractures.
- Surgery — debulking, contracture release, autoamputation prevention; full-thickness grafting; specialist hand / foot surgery.
- Targeted / pathway-directed therapy:
- Erlotinib (EGFR inhibitor) has case-series / case-report evidence for TRPV3-associated Olmsted syndrome through EGFR-transactivation blockade; use is off-label and should sit with specialist dermatology / genetics discussion.
- Genetic counselling and prenatal diagnosis.
- Cancer surveillance:
- Annual full-skin examination (lower threshold for biopsy of any change).
- Patient self-monitoring.
- Photoprotection counselling.
- Pruritus management — antihistamines (limited efficacy); gabapentin / pregabalin; selective serotonin reuptake inhibitors; cooling; emollient bath additives.
References
- Lin Z et al. Exome sequencing reveals mutations in TRPV3 as a cause of Olmsted syndrome. Am J Hum Genet; 2012.
- Duchatelet S, Hovnanian A. Olmsted syndrome — clinical and molecular review. Orphanet J Rare Dis; 2015.
Spot a correction?
If any clinical statement, citation or link on this page needs updating, please email admin@skinoncology.net with the page name, the proposed correction and the supporting source.